Almost 20 million people worldwide were living with rheumatoid arthritis in 2017, with over a million new cases diagnosed each year, according to estimates from the Global Burden of Diseases, Injuries, and Risk Factors Study.
Michael Ward talks about what’s new in the updated US guidelines for the management of ankylosing spondylitis and nonradiographic axial spondyloarthritis.
Dislocation risk following total hip replacement is declining with time and is associated with a number of surgical, hospital, and patient-related factors that are generally modifiable, UK researchers report.
Treatment with the interleukin-1 inhibitor anakinra improves both glycemic and inflammatory endpoints among patients with rheumatoid arthritis and type 2 diabetes, suggest findings from the TRACK trial.
Ustekinumab elicits a greater clinical response versus placebo in patients with psoriatic arthritis naïve to tumor necrosis factor inhibitors, regardless of prior conventional synthetic DMARD or methotrexate exposure, PSUMMIT 1 and PSUMMIT 2 study data show.
Almost 20 million people worldwide were living with rheumatoid arthritis in 2017, with over a million new cases diagnosed each year, according to estimates from the Global Burden of Diseases, Injuries, and Risk Factors Study.
Follow-up results from the TICOPA study suggest no long-term clinical advantage of an early treat-to-target strategy for patients with psoriatic arthritis.
Michael Ward talks about what’s new in the updated US guidelines for the management of ankylosing spondylitis and nonradiographic axial spondyloarthritis.
medwireNews takes a look at the efficacy and safety profiles of JAK inhibitors for the treatment of rheumatoid arthritis, and addresses some common questions about their use.
Rheumatoid arthritis patients treated with the JAK1 selective inhibitor upadacitinib experience greater improvement in the signs and symptoms of disease than those given placebo or adalimumab, indicate findings from the SELECT-COMPARE trial.
The anti‐nerve growth factor monoclonal antibody fasinumab improves pain and function in patients with knee or hip osteoarthritis who have a history of inadequate response or intolerance to analgesics, study findings indicate.
James Rosenbaum and Mark Asquith discuss how the microbiome interacts with the immune system, how this may induce inflammation, and how the microbiome could be used as a therapeutic target for rheumatic diseases.
